{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:19:05Z","timestamp":1789528745582,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jemermed.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T15:21:18Z","timestamp":1659194478000},"page":"17-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0335-5184","authenticated-orcid":false,"given":"Jeffrey D.","family":"Sperry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Eric","family":"Medow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2022.05.011_bib0001","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0004","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","article-title":"Mechanism of action of nonsteroidal anti-inflammatory drugs","volume":"104","author":"Vane","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.21469","article-title":"Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment","volume":"84","author":"Ageno","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0006","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ajh.21470","article-title":"Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 1: trevention","volume":"84","author":"Garcia","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0007","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.jemermed.2022.05.011_bib0008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1538-7836.2009.03429.x","article-title":"Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents","volume":"7","author":"Crowther","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0009","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2516.2011.02723.x","article-title":"Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment","volume":"18","author":"Berntorp","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0011","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0012","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0013","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00001721-200405001-00005","article-title":"Systematic review of the management of patients with haemophilia A and inhibitors","volume":"15","author":"Markis","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0014","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3121\/cmr.2014.1237","article-title":"The emergent reversal of coagulopathies encountered in neurosurgery and neurology: a technical note","volume":"13","author":"Medow","year":"2015","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0016","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0018","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0019","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0021","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0022","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12028-014-9972-0","article-title":"Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage","volume":"21","author":"Frontera","year":"2014","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0023","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/CIRCULATIONAHA.113.001875","article-title":"Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department","volume":"128","author":"Hickey","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0024","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: a systematic review and meta-analysis","volume":"116","author":"Chai-Adisaksopha","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000117811","article-title":"Transfusion-related acute lung injury: incidence, pathogenesis and the role of multicomponent apheresis in its prevention","volume":"35","author":"Popovsky","year":"2008","journal-title":"Transfus Med Hemotherap"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0026","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1345\/aph.1R497","article-title":"Vitamin K dosing to reverse warfarin based on INR, route of administration and home warfarin dose in the acute\/critical care setting","volume":"46","author":"Tsu","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12028-016-0248-8","article-title":"Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis","volume":"26","author":"Abdoellakhan","year":"2017","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0028","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1060028015585344","article-title":"Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant","volume":"49","author":"Kantorovich","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0029","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.ajem.2015.05.017","article-title":"Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal","volume":"33","author":"Klein","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/000313481508100632","article-title":"Less is more: low-dose prothrombin complex concentrate effective in acute care surgery patients","volume":"81","author":"Quick","year":"2015","journal-title":"Am Surg"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0031","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1537-2995.2012.03924.x","article-title":"The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin","volume":"53","author":"Varga","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0032","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3324\/haematol.2012.063701","article-title":"An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies","volume":"97","author":"Khorsand","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0033","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12185-021-03176-w","article-title":"Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal","volume":"114","author":"Bizzell","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0034","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.ajem.2020.06.017","article-title":"Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal","volume":"38","author":"Dietrich","year":"2020","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0035","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/1060028021992142","article-title":"Evaluation of a fixed-dose regimen of 4-factor prothrombin complex concentrate for warfarin reversal","volume":"55","author":"McMahon","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0036","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0037","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0038","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0039","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jemermed.2020.04.049","article-title":"Comparison of hemostatic outcomes in patients receiving fixed-dose vs. weight-based 4-factor prothrombin complex concentrate","volume":"59","author":"Kim","year":"2020","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0885066619840992","article-title":"A low-dose 4F-PCC protocol for DOAC-associated intracranial hemorrhage","volume":"35","author":"Berger","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0041","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0885066618800657","article-title":"Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients","volume":"35","author":"Allison","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0042","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s11239-021-02412-8","article-title":"Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral factor Xa inhibitors","volume":"52","author":"Hormese","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0043","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-020-02154-z","article-title":"Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products","volume":"51","author":"Castillo","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0044","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s11239-021-02480-w","article-title":"Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis","volume":"52","author":"Milioglou","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0885066620916706","article-title":"Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor\u2013associated bleeding: a retrospective study","volume":"36","author":"Wilsey","year":"2021","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0046","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/jcph.1779","article-title":"Outcomes associated with 4-factor prothrombin complex concentrate administration to reverse oral factor Xa inhibitors in bleeding patients","volume":"61","author":"Highsmith","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0047","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0048","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0049","first-page":"2637","article-title":"Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis","volume":"25","author":"Luo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0050","doi-asserted-by":"crossref","first-page":"E1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0051","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0052","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0053","first-page":"1","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"00","author":"Ansell","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0054","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/bja\/aen255","article-title":"Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux","volume":"101","author":"Bordes","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0055","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/ajh.20652","article-title":"Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate","volume":"81","author":"Firozvi","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0056","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/svn-2019-000274","article-title":"Coagulopathy reversal in intracerebral haemorrhage","volume":"5","author":"Sweidan","year":"2020","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0057","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0022-5223(19)34638-0","article-title":"The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations","volume":"104","author":"Gratz","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0058","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/bjs.1800800616","article-title":"Use of desmopressin to prevent bleeding complications in patients treated with aspirin","volume":"80","author":"Flordal","year":"1993","journal-title":"Br J Surg"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0059","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12028-011-9619-3","article-title":"Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage","volume":"16","author":"Naidech","year":"2012","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.jvca.2007.05.009","article-title":"Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy","volume":"21","author":"Ranucci","year":"2007","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0061","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/CH-2008-1092","article-title":"Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel","volume":"39","author":"Leithauser","year":"2008","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0062","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jcpt.12130","article-title":"The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor","volume":"39","author":"Teng","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0063","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0064","first-page":"358","article-title":"Platelet transfusion: an unnecessary risk for mild traumatic brain injury patients on antiplatelet therapy","volume":"71","author":"Washington","year":"2011","journal-title":"J Trauma"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0065","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1179\/174313209X459129","article-title":"Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage","volume":"32","author":"Ducruet","year":"2010","journal-title":"Neurol Res"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0066","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.wneu.2020.03.216","article-title":"The role of platelet transfusions after intracranial hemorrhage in patients on antiplatelet agents: a systematic review and meta-analysis","volume":"141","author":"Brogi","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-57683-7","article-title":"Platelet transfusion in patients with aneurysmal subarachnoid hemorrhage is associated with poor clinical outcome","volume":"10","author":"Post","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0068","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-based ticagrelor reversal agent in healthy volunteers","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0069","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjh.15409","article-title":"How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults","volume":"182","author":"Grainger","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0070","first-page":"1","article-title":"Variability in response to cryoprecipitate treatment for hemostatic defects in uremia","volume":"63","author":"Triulzi","year":"1990","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0071","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/ncpneph0421","article-title":"Evidence-based treatment recommendations for uremic bleeding","volume":"3","author":"Hedges","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0072","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJM198012043032302","article-title":"Treatment of the bleeding tendency in uremia with cryoprecipitate","volume":"303","author":"Janson","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0073","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJM198609183151204","article-title":"Conjugated estrogens for the management of bleeding associated with renal failure","volume":"315","author":"Livio","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0074","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198301063080102","article-title":"Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia","volume":"308","author":"Mannucci","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0075","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0076","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000497287","article-title":"Emicizumab in the treatment of acquired haemophilia: a case report","volume":"46","author":"M\u00f6hnle","year":"2019","journal-title":"Transfus Med Hemotherapy"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0077","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11239-019-02018-1","article-title":"Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience","volume":"49","author":"Tran","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0078","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/jth.14827","article-title":"Guidance on the diagnosis and management of platelet-type von Willebrand disease: a communication from the Platelet Physiology Subcommittee of the ISTH","volume":"18","author":"Othman","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0079","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jemermed.2020.02.019","article-title":"Hemophilia and von Willebrand disease: a review of emergency department management","volume":"58","author":"Tebo","year":"2020","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.blre.2017.08.007","article-title":"Haemophilia B: where are we now and what does the future hold?","volume":"32","author":"Dolan","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0081","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0082","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1160\/TH15-09-0740","article-title":"Supportive management strategies for disseminated intravascular coagulation: an international consensus","volume":"115","author":"Squizzato","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0083","first-page":"1","article-title":"A comprehensive review of congenital platelet disorders, thrombocytopenias and thrombocytopathies","volume":"12","author":"Mohan","year":"2020","journal-title":"Cureus"},{"issue":"suppl 4","key":"10.1016\/j.jemermed.2022.05.011_bib0084","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2516.2012.02856.x","article-title":"Inherited platelet disorders","volume":"18","author":"Nurden","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccc.2016.03.004","article-title":"Hematological issues in liver disease","volume":"32","author":"Allison","year":"2016","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0086","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0087","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ajem.2018.10.032","article-title":"Acute liver failure: a review for emergency physicians","volume":"37","author":"Montrief","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0088","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOG.0000000000000635","article-title":"Coagulation testing and management in liver disease patients","volume":"36","author":"Stotts","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0089","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0090","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/jth.14809","article-title":"Management of major bleeds in patients with immune thrombocytopenia","volume":"18","author":"Mithoowani","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0091","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2141.2006.06343.x","article-title":"A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO","volume":"135","author":"Bolton-Maggs","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0092","series-title":"Bernard Soulier syndrome","author":"Almomani","year":"2021"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0093","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0094","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjh.17172","article-title":"Disseminated intravascular coagulation: epidemiology, biomarkers, and management","volume":"192","author":"Adelborg","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0096","series-title":"Platelet Transfusion","author":"Khan","year":"2021"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0097","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0098","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0099","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0100","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/j.1538-7836.2011.04424.x","article-title":"Fibrinogen replacement therapy for congenital fibrinogen deficiency","volume":"9","author":"Bornikova","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0101","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MBC.0000000000000029","article-title":"Factor XIII deficiency management: a review of the literature","volume":"25","author":"Odame","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jemermed.2022.05.011_bib0102","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.hoc.2021.07.009","article-title":"Factor XIII deficiency: a review of clinical presentation and management","volume":"35","author":"Pelcovits","year":"2021","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467922003249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467922003249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:56Z","timestamp":1760028596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467922003249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0736467922003249"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2022.05.011","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}